Guiding Management of Bethesda V Thyroid Nodules: The Role of Molecular Testing
Authors' conclusion
Our findings suggest that molecular profiling offers insights into risk stratification for Bethesda V thyroid lesions, demonstrating a very low incidence of aggressive pathology in the low-risk molecular group.
Study context
- Population
- Patients with Bethesda V cytology and final malignant histology who underwent molecular profiling, 2018–2021
- Participants
- 156 patients
- Exposure
- Intermediate-risk vs low-risk molecular variants
- No mutationn = 56
- Low-riskn = 49reference
- Intermediate-riskn = 45
- High-riskn = 1
- Outcome
- Aggressive disease (histopathological features per 2015 ATA guidelines)
Methodological detailsmulticentre
- Multicentre
Main finding
As reported in the abstract
Aggressive disease
P < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | Low-risk | Intermediate-risk |
|---|---|---|
| Predominant mutations | ||
| RAS mutations | 68.8% | — not stated in the abstract |
| BRAF V600E | — not stated in the abstract | 93.3% |
— not stated in the abstract
Malignant on final pathology
- Malignant Bethesda V nodules (of 161)
- 153 (95.0%)
Original publication
Guiding Management of Bethesda V Thyroid Nodules: The Role of Molecular Testing. Clin Endocrinol (Oxf). Published 18 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →